🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "huge turning point" in the fight against increasingly resistant strains of the bacteria, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are escalating globally, with data suggesting over 82 million instances annually. Especially elevated rates are reported in the African continent and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an important and timely step in the reality of growing infection rates, the spread of superbugs and the extremely scarce therapeutic options currently available.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance found that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Receive Approval

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Researchers anticipate that specific application of this new drug will help delay the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is employed against UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a unique collaborative effort for medication research. The charitable organization GARDP collaborated with the drug firm Innoviva to develop it.

“This authorization marks a major breakthrough in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Data and Worldwide Availability

Based on data published in a prominent scientific publication, the new drug cured more than 90% of cases of the STI. This puts it on an similar efficacy with the current standard treatment, which involves an injection and a pill. The trial included hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the rights to license and sell the drug in many low-income and middle-income countries.

Doctors on the front lines have voiced hope. The availability of a single-dose, oral treatment of this kind is described as a "critical tool" for public health efforts. This is deemed essential to reduce the burden of the illness for people and to halt the transmission of extremely resistant gonorrhoea around the world.